Company Description
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa.
The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.
Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Apr 16, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 205 |
| CEO | Brian McKelligon |
Contact Details
Address: 100 Campus Drive, 6th Floor Marlborough, Massachusetts 01752 United States | |
| Phone | 855 896 8401 |
| Website | akoyabio.com |
Stock Details
| Ticker Symbol | AKYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001711933 |
| CUSIP Number | 00974H104 |
| ISIN Number | US00974H1041 |
| Employer ID | 47-5586242 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Brian McKelligon | President, Chief Executive Officer and Director |
| John Frederick Ek CPA | Chief Financial Officer and Principal Accounting Officer |
| Dr. Niroshan Ramachandran Ph.D. | Chief Business Officer |
| Anthony Catalano | Senior Vice President of Operations |
| Priyam Shah | Senior Director of Business Development and Investor Relations Strategy |
| Jennifer Kamocsay | Chief Legal Officer |
| Dr. Pascal Bamford Ph.D. | Chief Clinical Officer |
| Rob C. Hart C.F.A., CFA, J.D. | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 8, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 8, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 8, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 8, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 8, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jul 8, 2025 | 25-NSE | Filing |
| Jul 8, 2025 | 8-K | Current Report |
| Jul 7, 2025 | 8-K | Current Report |
| Jun 16, 2025 | DEFM14A | Filing |